Treatment of patients with Eisenmenger's syndrome with Bosentan

Cardiol Young. 2007 Jun;17(3):288-94. doi: 10.1017/S1047951107000522. Epub 2007 Apr 23.

Abstract

We treated prospectively 14 patients with Eisenmenger's syndrome, with a mean age of 10 years, ranging from 3 to 18 years. Treatment continued for 12 months, and demonstrated a lasting symptomatic improvement, but no improvement in terms of mean saturation of oxygen over 24 hours. Exercise capacity, as judged by peak uptake of oxygen, worsened in the six patients able to perform a treadmill test. The symptomatic benefit from dual blockage of endothelin receptors in these patients may be due to mechanisms other than selective pulmonary vasodilatation alone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / therapeutic use*
  • Bosentan
  • Child
  • Child, Preschool
  • Eisenmenger Complex / drug therapy*
  • Eisenmenger Complex / physiopathology
  • Exercise Test
  • Female
  • Humans
  • Male
  • Oximetry
  • Prospective Studies
  • Sulfonamides / administration & dosage
  • Sulfonamides / therapeutic use*
  • Treatment Outcome

Substances

  • Antihypertensive Agents
  • Sulfonamides
  • Bosentan